WASHINGTON, DC (July 16, 2018) — LUNGevity Foundation, the nation’s leading lung cancer-focused nonprofit organization, announced today that Jennifer Kashatus, a long-term privacy and cybersecurity professional and partner at DLA Piper LLP, has joined the Board of Directors. Kashatus brings an indispensable perspective from an industry new to LUNGevity’s board while offering her expertise to further LUNGevity’s work of changing outcomes for people with lung cancer.
“We are honored to have Jennifer join our board,” said Andrea Ferris, president and CEO of LUNGevity Foundation. “She brings extensive volunteer experience in the Washington area. Her professional acumen will help guide LUNGevity on partnering opportunities in many areas. We look forward to working with her to build LUNGevity’s presence.”
Jennifer routinely advises companies in all industry sectors on privacy and cybersecurity issues. In particular, Jennifer assists companies in developing comprehensive global and domestic privacy and data security programs, guiding companies in navigating the myriad state, federal, and international privacy regulations. Jennifer also devotes a significant portion of her practice to incident response and preparation, having advised numerous companies on the implementation of an incident response program and coaching companies through evaluating and responding to a threatened or actual security incident. Further, Jennifer routinely advises clients on privacy and data security matters in the context of corporate transactions, working with clients to identify potential risks in an acquisition, whether buy or sell side.
Jennifer has also worked with multiple state, federal, and international regulations. This will be invaluable as LUNGevity continues its policy work to improve regulations and legislation impacting lung cancer patients.
About LUNGevity Foundation
LUNGevity is the nation's leading lung cancer organization investing in lifesaving, translational research and providing support services and education for patients and caregivers. LUNGevity’s goals are three-fold: (1) accelerate research to patients, (2) empower patients to be active participants in their treatment decisions, and (3) remove barriers that patients face in accessing the right treatments.
LUNGevity Foundation is firmly committed to making an immediate impact on increasing quality of life and survivorship of people with lung cancer by accelerating research into early detection and more effective treatments, as well as by providing community, support, and education for all those affected by the disease. LUNGevity’s comprehensive resources include a medically vetted website, a toll-free HELPLine in partnership with CancerCare®, a unique Lung Cancer Navigator app, peer-to-peer mentoring for patients and caregivers (LUNGevity LifeLine), and survivorship conferences. LUNGevity also helps patients find and navigate clinical trials through our Clinical Trial Finder tool, a Clinical Trial Ambassador program, and participation with EmergingMed.
Our vision is a world where no one dies of lung cancer. For more information about LUNGevity Foundation, a four-star Charity Navigator organization, please visit www.LUNGevity.org.
About Lung Cancer in the U.S.
- About 1 in 16 Americans will be diagnosed with lung cancer in their lifetime
- More than 234,000 people in the U.S. will be diagnosed with lung cancer this year
- About 60%-65% of all new lung cancer diagnoses are among people who have never smoked or are former smokers
- Lung cancer takes more lives than the next three leading cancers (colorectal, breast, and prostate) combined
- Only 19% of all people diagnosed with lung cancer will survive 5 years or more, BUT if it’s caught before it spreads, the chance of 5-year survival improves dramatically